Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor by Kakoki, M. et al.
Diabetic nephropathy is markedly enhanced in mice
lacking the bradykinin B2 receptor
Masao Kakoki*, Nobuyuki Takahashi*, J. Charles Jennette, and Oliver Smithies†
Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599
Contributed by Oliver Smithies, July 29, 2004
Type I human diabetics and streptozotocin-induced diabetic mice
with higher genetically determined levels of angiotensin-convert-
ing enzyme have an increased risk of developing nephropathy.
However, previous experiments in mice and computer simulations
indicate that modest increases in angiotensin-converting enzyme
have minimal effects on blood pressure and angiotensin II levels,
although bradykinin decreases significantly, inferring that brady-
kinin is critical for protecting the kidney in diabetics. Here, we
confirm this inference by demonstrating that Akita diabetic mice
lacking the bradykinin B2 receptor develop overt albuminuria,
excreting the equivalent of >550 mgday albumin in humans,
which contrasts with the microalbuminuria (equivalent to <150
mgday) seen in their simply diabetic littermates. The overt albu-
minuria is accompanied by a marked increase in glomerular mes-
angial sclerosis. The importance of bradykinin demonstrated here
bears strongly on how current drugs reduce diabetic nephropathy
and suggests that B2 receptor-specific agonists merit consideration
in this context.
maturity onset diabetes of the young  albuminuria  glomerulosclerosis
D ifferences in expression of the gene coding for angiotensin-converting enzyme (ACE), such as are observed in humans
in relation to the insertiondeletion polymorphism in the ACE
gene (1) and in mice with different numbers of the gene (2), have
minimal effects on angiotensin II (ANGII) levels because the
steady-state concentrations of the products of ACE are less
sensitive to modest changes in the activity of the enzyme than the
concentrations of its substrates. Thus, our recent computer
simulations (3, 4) and accompanying experimental data indicate
that a 50% increase in ACE causes a 5% increase in steady-
state ANGII levels but close to a 20% decrease in bradykinin
levels. Hence, our inference that the causative link between
genetic differences in ACE expression and diabetic nephropathy
(5, 6) is likely to be mediated by the ACE substrate bradykinin.
To test this inference, we have combined the following two
mutations: a dominant mutation that leads to maturity onset
diabetes, Akita (7), resulting from an amino acid change in the
insulin 2 gene (Ins2C96Y) (8), and a recessive knockout mutation
(Bdkrb2) (9) in the gene coding for the bradykinin B2 receptor,
the receptor predominantly expressed in the normal kidney.
Materials and Methods
Animals. Animals were purchased from The Jackson Laboratory
and bred in our mouse facility. The mice having the null allele
for the bradykinin B2 receptor (9) were backcrossed to wild-type
C57BL6J at least six times before mating to mice heterozygous
for the Akita mutation (Ins2/C96Y) (7), which already have the
C57BL6J genetic background. All experiments were conducted
in accordance with the guidelines of the University of North
Carolina Institutional Animal Care and Use Committee. Blood
pressures were measured as described (2). Plasma glucose levels
were determined with the glucose-oxidase method (Wako, Rich-
mond, VA). Urinary albumin was determined with ELISA
(Exocell M, Philadelphia).
Quantitative RT-PCR. Total RNA was extracted from the whole
right kidney of mice, and the mRNA expression of the brady-
kinin B1 and B2 receptors and of megsin and nephrin was
determined by quantitative RT-PCR as described (10). Primers
for the amplification and probes for detecting and measuring the
expression of these genes are provided in Table 3, which is
published as supporting information on the PNAS web site.
Sense RNAs synthesized from a cDNA fragment cloned into
pBluescript II (Stratagene) for each of the genes of interest were
used for calibrating quantitation of their messages.
Results
Males with the following four combinations of mutations were
generated: wild type at both loci; mutant (homozygous knock-
out) only at the Bdkrb2 locus; mutant (heterozygous Akita) only
at the Ins2 locus; and mutant at both loci. Basic parameters,
including body, heart, and kidney weights, as well as blood
pressure, plasma glucose, food intake, urine volume, and daily
excretion of albumin, were determined for each animal (Table
1). Comparison of the singly mutant B2 receptor knockout males
with their wild-type littermates showed that the receptor knock-
out animals do not differ significantly from wild type in any of
these parameters, which is in general agreement with a previous
report (11) for the same null mutation. Heterozygous males for
the dominant Akita mutation (Akita diabetic) have severe
diabetes at 6 months of age with 38.8  1.9 mmolliter (698 
34 mgdl) plasma glucose. Their body weights are 70% of wild
type; they consume more than three times the normal amount of
food, and their urine outputs are 20 times those of wild type.
Doubly mutant males (Akita diabetic and bradykinin B2 recep-
tor null) are indistinguishable from the singly mutant Akita
diabetic animals in all these parameters (including plasma
glucose, food intake, and urine volume), except for two param-
eters indicative of nephropathy: kidney weight and albumin
excretion.
Kidneys are enlarged in human insulin-dependent diabetics,
and more so when they have microalbuminuria or overt levels of
albumin excretion (12). In the singly mutant Akita diabetic mice,
the kidney weightbody weight ratio was 11.4  0.9 versus 5.8 
0.3 in wild-type mice (P  0.05). In the doubly mutant mice, this
ratio (13.5  0.5) was significantly greater than in either the
singly mutant Akita diabetic mice (P  0.05) or the wild-type
mice (P  0.001).
Urinary daily albumin excretion is a more specific indicator of
nephropathy than kidney weight. In the double mutants, it
reached the level of overt albuminuria (209  40 gday,
equivalent to 550 mgday in humans), as shown in Fig. 1 (P 
0.0001 for double mutant versus wild type). This overt albumin-
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uria contrasts with the microalbuminuria (54  12 gday,
equivalent to 150 mgday in humans) occurring in the singly
mutant Akita diabetic mice (P  0.005 for double mutant versus
Akita).
Fig. 2 shows that absence of the bradykinin B2 receptor alone
leads to no histological changes in the kidney at 6 months of age.
The Akita diabetogenic mutation alone causes some changes,
including glycogen deposits in tubular cells and a minor degree
of mesangial sclerosis in some glomeruli. In the double mutants,
the glycogen accumulation is not obviously different from that
in their singly mutant littermates. However, the glomerular
mesangial sclerosis is markedly increased and more closely
resembles glomerular changes that are seen in human patients
with diabetic glomerulosclerosis. Electron micrographs (Fig. 3)
confirm the mesangial matrix expansion in the double mutants,
but they do not show any obvious changes in the glomerular
endothelial cells or podocytes. In general agreement with a
previous report (13), immunofluorescence microscopy demon-
strates the presence of mesangial Ig in our singly mutant Akita
diabetic mice, including IgG, IgA, and IgM, with no obvious
difference when the mice also lack the B2 receptor (data not
shown).
To assess the general status of the four groups of animals
and to look for possible compensatory changes, we used
quantitative RT-PCR to determine renal mRNA expression of
both bradykinin receptors (B1 and B2) and several other
informative genes. Table 2 presents the resulting data. Ex-
pression of the B2 receptor in the B2 receptor null animals is,
as expected (9), indistinguishable from zero. We also confirm
a previous report (14) that, in the B2 null animals expression
of the bradykinin B1 receptor, expressed only weakly in
wild-type kidneys, is markedly enhanced (12 times wild
type), reaching a level comparable with wild-type expression
of the B2 receptor. A similar increase in B1 receptor expres-
sion is seen in the singly mutant Akita diabetic animals (to 11
times that of wild type), even though expression of the B2
receptor in these animals is also increased (to approximately
two times that of wild type). Expression of the B1 receptor in
the double mutants is increased further to 25 times that of
wild type, becoming greater than wild-type expression of the
B2 receptor. However, despite this very marked increase in
expression of the B1 receptor in the Akita diabetic B2 receptor
null mice, the nephropathy is not prevented.
Megsin, a member of the serpin family of protease inhibi-
tors, appears to be an inhibitor of matrix protein degradation
in the mesangium (15). Its expression is unchanged in the
receptor null mice but is increased to approximately two times
that of wild type in the singly mutant Akita diabetic mice and
to approximately three times that of wild type in the double
mutants, which may be related to the extent of mesangial
matrix expansion. Expression of nephrin, an essential compo-
nent of the slit diaphragms of the glomerulus, is increased at
early stages in rats that were made diabetic by streptozotocin
(16). We found that nephrin expression is approximately two
times that of wild type in our Akita diabetic mice and
approximately four times that of wild type in the double
mutants. This finding is in agreement with the absence of any
Fig. 1. Daily urinary albumin excretion in 6-month-old male mice. Genotypes
are wild type at both the insulin 2 and the bradykinin B2 loci (WT  Ins2/,
Bdkrb2 /); wild type for insulin and homozygous null for the B2 receptor
(B2/  Ins2/, Bdkrb2/); heterozygous Akita for insulin and wild type for
the B2 receptor (Akita  Ins2/C96Y, Bdkrb2/); and doubly mutant (Double 
Ins2/C96Y, Bdkrb2/). P  0.04, 0.0005, and 0.0001 for wild type versus B2
null, Akita diabetic, and double mutant mice, respectively. P  0.0003 and
0.0001 for B2 null versus Akita diabetic and double mutant mice, respec-
tively. P  0.004 for Akita diabetic versus double mutant mice.
Table 1. Characteristics of 6-month-old males having the four combinations of wild-type and










Number 4 4 9 7
BW, g 36.8  1.2 34.2  3.5 24.7  2.0† 24.6  1.4†
HW, mg 203  16 200  31 150  11* 157  12*
HWBW, mgg 5.5  0.5 5.9  0.6 6.3  0.6 6.4  0.4
KW, mg 212  7 237  19 274  21 330  18†‡
KWBW, mgg 5.8  0.3 6.9  1.9 11.4  0.9† 13.5  0.5†‡
Blood pressure, mmHg
(1 mmHg  133 Pa)
118  3 124  5 123  3 126  4
Hematocrit, % 42.8  2.1 44.0  0.5 45.9  1.8 46.2  1.6
Plasma glucose, mmolliter 10.9  1.3 8.2  1.4 38.8  1.9† 37.9  1.4†
Food intake, gday 3.5  0.3 3.9  0.8 12.2  1.5* 14.0  2.6*
Urine volume, mlday 1.3  0.1 1.2  0.1 26.1  4.6* 33.0  6.7*
Urinary albumin, gday 7.6  2.0 11.0  3.0 54  12* 209  40†§
Data are given as mean  SEM. BW, body weight; HW, heart weight; KW, kidney weight.
*P  0.05.
†P  0.001 vs. wild type.
‡P  0.05.
§P  0.001 vs Bdkrb2 Ins2C96Y.











obvious podocyte losses in the electron micrographs of the
glomeruli of these animals.
Discussion
The sequence of events that leads to the increased nephrop-
athy that we observe in diabetic mice lacking the bradykinin B2
receptor is not immediately apparent, although it is clear that
the B1 receptor cannot compensate for its absence. Mesangial
cells are potential mediators of the glomerular damage that we
report in this article because they express the B2 receptor and
respond in various ways to bradykinin (17, 18). However, the
increase in interstitial fibrosis that we find in the diabetic mice
Fig. 2. Photomicrographs of the kidneys with the same four genotypes as shown in Fig. 1. (A) Masson’s trichrome staining of renal cortex. (Original
magnification, 40.) (B) Periodic acid-Schiff staining of glomeruli counterstained with hematoxylin. (Original magnification, 400.)
Fig. 3. Electron micrographs of kidneys with the same four genotypes as shown in Fig. 1. (Original magnification, 5,000.)
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lacking the B2 receptor suggests that the increased nephrop-
athy in the double mutants must involve events additional to
those mediated by mesangial cells. Despite remaining ques-
tions, our experiments bear directly on the interpretation of
the well known merits of ACE inhibitors in preventing diabetic
nephropathy. Thus, current thinking usually ascribes this
protection to decreases in ANGII levels. Our data suggest that
increases in bradykinin levels are also important and that B2
receptor-specific agonists are likely to be protective without
the side effects induced by stimulating B1 receptors.
In summary, we conclude that the bradykinin system plays a
critical role in protecting the kidney from damage caused by
diabetes mellitus, and we emphasize the importance of enhanc-
ing the action of kinins as a means of minimizing this diabetic
complication.
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Table 2. The amount of mRNA in the kidney of the four groups of animals
Genotype Bdkrb2 Ins2 Bdkrb2 Ins2 Bdkrb2 Ins2C96Y Bdkrb2 Ins2C96Y
B2 receptor 32.8  4.3 (100  13) 0.0  0.0* (0  0) 67.7  12.7* (207  39) 0.0  0.0*† (0  0)
B1 receptor 3.1  0.4 (100  13) 35.2  3.4* (1,132  109) 37.1  2.1* (1,196  67) 78.0  8.0*† (2,511  257)
Megsin 0.257  0.034 (100  13) 0.306  0.040 (119  16) 0.462  0.049* (180  19) 0.831  0.105*† (323  41)
Nephrin 1.44  0.19 (100  13) 1.61  0.16 (112  11) 3.03  0.39* (210  27) 4.47  0.28*† (310  19)
Data are given as pg mRNA of genes of interest in g total RNA (mean  SEM). Relative expression levels (% wild type) are shown in parentheses.
*P  0.05 vs. wild type.
†P  0.05 vs. Bdkrb2 Ins2C96Y.
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